Načítá se...
DDIS-15. A NOVEL DOPAMINE RECEPTOR 3 ANTAGONIST INHIBITS THE GROWTH OF PRIMARY AND TEMOZOLOMIDE RESISTANT GLIOBLASTOMA CELLS
Glioblastoma (GBM) is the most common, lethal primary adult brain tumor with patient survival of only 14 months. The location and invasion of GBM leads to rapid recurrence after therapy. The standard of care chemotherapy is DNA damaging agent temozolomide (TMZ), to which resistance is common and is...
Uloženo v:
| Vydáno v: | Neuro Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216607/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.294 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|